Background and Objectives: Various adiposity indicators have been used to predict metabolic syndrome (MetS). The aim of the present study was to evaluate the predictive ability of known adiposity indicators, such as abdominal girth, girth/height and fat percentage, as well as less commonly used indicators, such as the conicity index (CI), body roundness index (BRI), visceral adiposity index (VAI) and body shape index (ABSI), to predict MetS. Materials and Methods: A total of 261 participants, including family members and graduates of a flagship school in the city of Trujillo, Peru, participated. Metabolic syndrome was assessed according to the harmonised ATP III criteria. ROC curves were analysed for each of the adiposity indicators using SPSS 26.0 statistical software. Results: The prevalence of MetS was found to be 43.4%, with a higher proportion in men (25.8%). The area under the curve (AUC) for the prediction of MetS exceeded a value of 0.8 for VAI, abdominal circumference, circumference/height and relative fat mass in both men and women, with VAI showing the highest values of 0.858 and 0.875 in women and men, with cut-off points for MetS of 2.57 and 1.73, respectively. Conclusions: VAI can be used in the diagnosis of metabolic syndrome during lipid profile and anthropometric assessment.

Cardiac troponin serum concentration is a marker of myocardial injury, but NT-pro BNP is a marker of myocardial insufficiency. The purpose of this study was to determine binary logistic regression models to verify the possible association of cardiovascular risk indicators, pre-pandemic history, the number of times participants were infected with SARS-CoV-2, and vaccination against these biomarkers. A total of 281 residents of Trujillo city (Peru) participated between September and December 2023. We found a high prevalence of abdominal obesity of 55.2%; glycemia > 100 m/dL in 53%; hypercholesterolemia in 49.8%; low HDL in 71.9%; and LDL > 100 mg/dL in 78.6%. A total of 97.5% were vaccinated against COVID-19, and 92.2% had three or more doses. Also, 2.5% had cTnI > 0.05 ng/mL, and 3.3% had NT-proBNP > 125 pg/mL. The number of COVID-19 infections versus cTnI > 0.05 ng/mL presented an OR = 3.513 (p = 0.003), while for NT-proBNP > 125 pg/mL, the number of comorbidities presented an OR = 2.185 (p = 0.025) and LDL an OR = 0.209 (p = 0.025). A regression model was obtained in which there is an association between a higher number of COVID-19 infections and elevated cTnI values and a model implying an association of the number of comorbidities and LDL with the NT-proBNP level in a direct and inverse manner, respectively. Both models contribute to the prevention of cardiac damage.